dpp4i and glp 1 agonist The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect DPP4 in Diabetes - PMC
Description
p = 0.001), fatal and non-fatal myocardial infarction (HR 0.90, 95% CI: 0.830.98

por ms que existan patrones atractivos, no hay estrategias infalibles, solo mtodos para administrar mejor el riesgo

Credit: Jrnvall, Agerberth, Zasloff

The Food and Drugs Association (FDA) has approved two types of GLP-1 drugs for weight loss

However, the long-term implications of prolonged GLP-1 medication use remain a topic of ongoing research and debate, Thompson says

Meanwhile these agents have the potential to reduce major adverse cardiovascular events (MACE) in patient with T2DM as a drug class, individual drugs have different potency and effects they need tailored approach to align with patient treatment goals rather than generalized use (117)
